Intermediate Retest Date vs Expiry Date: What Buyers Must Know

The Date on Your COA That Most Buyers Misread

Every pharmaceutical intermediate COA carries a date line. Some call it “retest date.” Others write “expiry date.” A few just print “shelf life.” Most buyers treat these as the same thing — a cutoff after which the material should not be used.

They are not the same thing. The difference between a retest date and an expiry date determines whether a batch of intermediate can be salvaged after the printed date or must be discarded. For a procurement manager ordering 500 kg of a chiral building block, that distinction can mean the difference between a usable shipment and a written-off loss.

This article explains what each term means under ICH guidelines, why pharmaceutical intermediates carry retest dates rather than expiry dates, and what a buyer should actually look for — and ask — when evaluating date labels on a supplier’s COA.

Three Terms, Three Meanings — Defined by ICH

The definitions come from ICH Q1A(R2), the foundational stability testing guideline, and ICH Q7, the GMP guide for active pharmaceutical ingredients. Here are the authoritative definitions:

Retest Date: The date after which samples of the drug substance should be examined to ensure that the material is still in compliance with the specification and thus suitable for use in the manufacture of a given drug product. — ICH Q1A(R2), ICH Q7

Expiry Date (Expiration Date): The date placed on the container label of a drug product designating the time during which a product is expected to remain within specifications — after which it shall not be used. — ICH Q1A(R2)

Shelf Life (Expiration Dating Period): The time period during which a drug product is expected to remain within the approved shelf life specification, provided that it is stored under the conditions defined on the container label. — ICH Q1A(R2)

These definitions are not interchangeable. The key regulatory distinction is clear:

Key Takeaway: A retest date is a checkpoint, not a finish line. After a retest date, you re-examine the material. If it passes, you use it. An expiry date is a finish line. After it, the product is done — no retesting, no extension without regulatory approval.

Why Intermediates Use Retest Dates — Not Expiry Dates

ICH Q7 Section 11.61 states explicitly:

“An API expiry or retest date should be based on an evaluation of data derived from stability studies. Common practice is to use a retest date, not an expiration date.” — ICH Q7, Section 11.6

This is not a stylistic preference. There are three practical reasons why retest dates, not expiry dates, are standard for intermediates and APIs:

1. Intermediates Are Not Finished Products

An expiry date applies to a drug product — a finished dosage form that a patient will consume. The regulatory logic is: once the expiry date passes, the product’s safety and efficacy cannot be guaranteed, and it must not be used. Intermediates are starting materials or building blocks.

They are not administered to anyone. Their quality function is to meet specification so that downstream synthesis can proceed reliably. If they still meet specification after the printed date, they can still perform that function.

2. Retestability Reflects Real Chemical Behavior

Most pharmaceutical intermediates are relatively stable organic compounds. Their degradation kinetics under controlled storage conditions (typically 25 °C ± 2 °C / 60% RH ± 5% per ICH Q1A) are often slow enough that the material remains within specification well beyond the initially assigned retest period.

A retest date acknowledges this reality: rather than declaring the material “expired,” it triggers a verification step. If the material passes retest, it is still suitable for use.

3. Stability Data for Intermediates Is Often Limited

Unlike finished drug products, which undergo full long-term, accelerated, and intermediate stability programs per ICH Q1A, many intermediates do not have complete stability datasets.

A manufacturer may assign a conservative initial retest period (e.g., 12 or 24 months) based on accelerated stability data or structural analogy, with the expectation that the period can be extended as more real-time data accumulates. An expiry date, by contrast, is a firm endpoint that cannot be revised without a formal regulatory submission.

Key Takeaway: If a supplier prints “expiry date” on an intermediate COA instead of “retest date,” that is not just a terminology mistake — it fundamentally changes what you can do with the material after that date. An intermediate with an expiry date cannot legally be retested and reused. An intermediate with a retest date can.

The Intermediate Regulatory Gap: Where ICH Guidance Is Less Defined

Here is where the conversation becomes more nuanced — and where most existing guidance falls short.

ICH Q1A(R2) and ICH Q7 primarily address drug substances (APIs). The retest date concept, as defined in these guidelines, applies to drug substances. Pharmaceutical intermediates, however, occupy a distinct regulatory position defined by ICH Q11:

“If an isolated intermediate is proposed as the starting material for a semi-synthetic drug substance, the applicant should provide a justification that explains how the proposed starting material complies with the general principles for the selection of starting materials.” — ICH Q11, Section 5.1.1

An intermediate designated as an API starting material falls under ICH Q11’s justification requirements — but ICH Q11 does not prescribe specific stability testing obligations for that starting material.

The stability data requirements for the starting material are determined during drug substance development and are described in the CTD Module 3.2.S.7 (drug substance stability).

The starting material’s own stability profile is typically addressed through the drug substance’s overall control strategy rather than through a standalone stability program.

This creates a practical gap:

For a manufacturer of intermediates, this means the retest date assignment process must be self-driven. There is no ICH template that dictates exactly what stability data must be generated for an intermediate before assigning a retest period.

The manufacturer must design and execute an appropriate stability program based on the intermediate’s chemical properties, intended use, and risk profile.

How a Manufacturer Sets Retest Dates for Intermediates

At our facility, the process for assigning a retest period to a pharmaceutical intermediate follows a risk-based framework informed by ICH principles and published methodology.

The approach is adapted from the risk-based retest date methodology described by Charoo et al. (2024) in Pharmaceuticals, which proposes a systematic three-step process for APIs. We apply a similar logic calibrated for intermediates:

Step 1: Identify Critical Material Attributes

Before assigning any retest period, we identify which properties of the intermediate must remain within specification for downstream use. These include:

• Chemical purity and impurity profile— degradation products must stay below specification limits
• Chiral purity— for chiral intermediates, enantiomeric excess must remain within range
• Residual solvent levels— must stay below ICH Q3C limits
• Water content— hygroscopic intermediates may gain moisture during storage, affecting assay and reactivity
• Physical form— crystalline form, particle size, and color/appearance must remain consistent

Not every attribute carries equal risk. A non-hygroscopic, achiral intermediate with no known polymorphic forms presents a lower stability risk than a hygroscopic, chiral compound with documented polymorphic transitions. The retest period reflects this difference.

Step 2: Generate Stability Data

We conduct stability studies under ICH-defined conditions:

Storage conditions per ICH Q1A(R2). Stress testing scope per ICH Q1A(R2) Section 2.2.1 for new drug substances.

If the accelerated study shows no significant change within 6 months, and the long-term data confirms stability at 12 months, a conservative initial retest period can be assigned — typically 12 months, with the option to extend as additional long-term data accumulates.

Step 3: Assign the Retest Period Based on Risk

The initial retest period reflects the stability data generated and the risk profile of the intermediate:

Risk categories adapted from Charoo et al. (2024), “Risk-Based Approach for Defining Retest Dates for Active Pharmaceutical Ingredients and Excipients,” Pharmaceuticals 17(7):903.

Key Takeaway: A shorter retest period on an intermediate COA does not necessarily mean the material is less stable.

It often means the manufacturer has less long-term stability data for that specific compound and is assigning a conservative period until more data accumulates. A buyer should ask: “Is this retest period based on real-time data or on extrapolation from accelerated data?”

What Happens After a Retest Date: Retestability and the “Use Immediately” Question

ICH Q7 Section 11.6 states that after a retest date, a drug substance “should be re-examined” to verify it still meets specification. If it passes, the material can continue to be used.

But what does “continue to be used” actually mean in practice? The guidelines use the term “used immediately” — and this phrase has been a source of ongoing confusion in the industry.

A 2024 peer-reviewed paper by Charoo et al. addressed this gap directly. The paper noted that neither ICH Q1A(R2) nor ICH Q7 defines the duration of “immediate use” after a successful retest. The authors referenced a WHO Expert Committee on Specifications for Pharmaceutical Preparations (TRS 1010) recommendation that provides an operational definition:

After successful retest, the API may be used within one month of the retest date. A full new retest period equal to the original period should not be granted based on a single retest result. — WHO TRS 1010 interpretation, as cited in Charoo et al. (2024)

This is important for two reasons:

1. Retesting does not reset the clock to zero.A successful retest does not grant a new 24-month retest period. It grants a short window — typically one month per WHO guidance — during which the verified material can be used.
2. Multiple retests are allowed, but each must be documented.ICH Q7 does not limit the number of retests. However, each retest must be a full specification evaluation, and the results must be recorded. A pattern of repeated retesting with marginal pass results is a signal that the material’s stability is declining and should be evaluated critically.

Key Takeaway: If your supplier says “we can retest and extend the retest period,” ask what extension they assign. A scientifically justified extension after retest is typically 3–6 months based on new real-time stability data, not a full reset of the original period.

The WHO TRS 1010 position suggests a one-month window after a single retest — a far more conservative approach than some suppliers imply.

Red Flags on Intermediate COA Date Labels

When reviewing a pharmaceutical intermediate COA, the date-related fields reveal more than most buyers realize. Here are the specific red flags:

⚠️ “Expiry Date” printed on an intermediate COA
This is the most significant red flag. ICH Q7 §11.61 states that common practice for APIs and intermediates is to use a retest date, not an expiry date. If a supplier uses “expiry date” for an intermediate, either (a) they do not understand the regulatory distinction, or (b) they are intentionally assigning a firm endpoint that eliminates the buyer’s option to retest. Either interpretation is problematic.

⚠️ No date field at all on the COA
A COA without any retest date, expiry date, or manufacturing date is incomplete. ICH Q7 §11.6 requires that APIs carry a retest or expiry date. If the material is an intermediate, the same principle applies — the buyer needs to know when the material was produced and how long its quality claim is supported by data.

⚠️ Very long retest periods with no stability data reference
A 36-month or 48-month retest period on an intermediate COA, without any reference to the stability study that supports it, is a claim without evidence. Ask the supplier: “What stability data supports this retest period? Was it based on real-time data, accelerated data, or extrapolation per ICH Q1E?”

⚠️ Retest period identical across all intermediates
If a supplier assigns the same retest period (e.g., 24 months) to every intermediate in their catalog regardless of chemical properties, that period is likely a default value, not a compound-specific assignment.

Different intermediates have different stability profiles — a hygroscopic amino acid derivative and a stable aromatic hydrocarbon should not carry the same retest period.

The 2025 ICH Q1 Draft: What Changes for Drug Substance Shelf Life

In April 2025, ICH released the Step 2 draft of ICH Q1 — a comprehensive revision that consolidates and updates the Q1A through Q1F stability guidelines. This draft introduces a significant definitional change:

Shelf Life (Draft ICH Q1, Step 2, April 2025): “The time period during which a drug substance or drug product is expected to remain within the approved shelf life specification, provided that it is stored under the conditions defined on the label.”

The previous Q1A(R2) definition limited “shelf life” to drug products only. The draft Q1 extends it to drug substances as well. The retest date definition remains unchanged in the draft.

This change has a practical implication: once ICH Q1 reaches Step 4 and is adopted by regulatory authorities, drug substance shelf life will be an officially defined concept alongside retest date.

For manufacturers, this creates a clearer framework for presenting stability-based time claims for drug substances. For intermediates designated as starting materials, the impact is indirect — the new definition formalizes what many manufacturers already practice, but does not impose new stability testing obligations on intermediates specifically.

Source: ICH Q1EWG Step 2 Draft Guideline, April 2025. Available at database.ich.org.

Five Questions to Ask Your Supplier About Retest Dates

Before placing an order for a pharmaceutical intermediate, these five questions can reveal whether the supplier’s retest date practice is scientifically grounded or administratively convenient:

1. “Is the retest date on this COA based on real-time stability data or extrapolated from accelerated data?”
   Real-time data (≥12 months at 25 °C/60% RH) provides stronger evidence. Accelerated extrapolation per ICH Q1E is acceptable for initial assignment but should be verified as long-term data accumulates.
2. “Does your facility conduct compound-specific stability studies, or do you assign a default retest period across all intermediates?”
   A manufacturer who runs stability studies tailored to each intermediate’s risk profile is demonstrating a higher level of quality control than one who applies a blanket period.
3. “What stability conditions and duration were used to generate the data supporting this retest period?”
   The answer should reference specific ICH conditions (25 °C ± 2 °C / 60% RH ± 5% for long-term; 40 °C ± 2 °C / 75% RH ± 5% for accelerated) and the duration of testing.
4. “If I need to use the material after the retest date, what is your retest extension policy?”
   A scientifically grounded supplier will describe their retest procedure, the parameters tested, and the extension they assign — typically 3–6 months based on passing results, not a full reset.
5. “Can you share the stability summary data — not just the COA — for this intermediate?”
   A COA reports results for a single batch at a single time point. A stability summary shows how the material performs over time across multiple batches. A supplier willing to share stability summaries demonstrates transparency.

Key Takeaway: A retest date is only meaningful if it is supported by data. The COA tells you the date; the stability data tells you why the date was chosen. Ask for both.

Why This Matters for Procurement Decisions

The retest date on an intermediate COA is not a regulatory decoration — it is a data-backed claim about how long the material’s quality will remain within specification under defined storage conditions.

Understanding what that date means, how it was determined, and what your options are after it passes directly affects three practical procurement realities:

• Inventory planning: If a retest date is 12 months from manufacture, your receiving window and shelf planning must account for that timeline — and for the possibility of extension through retest.
• Cost risk: An intermediate past its retest date that fails retest must be discarded. The cost is not just the material price — it includes incoming QC labor, disposal, and the delay of finding a replacement shipment. 
• 📎 pharmaceutical intermediate pricing factors
• Supplier evaluation: How a manufacturer handles retest dates reveals their quality culture. A supplier who assigns compound-specific retest periods with documented stability data, and who can articulate a clear retest extension policy, operates a more rigorous quality system than one who prints “24 months” on every COA by default. 
• 📎 Supplier Audit Checklist

For a more detailed guide on what to look for across the entire COA — beyond just the date field — see our How to Read a COA for Pharmaceutical Intermediates.

Frequently Asked Questions

Can I use a pharmaceutical intermediate after its retest date?

Yes — unlike an expiry date, a retest date is a verification checkpoint, not a hard cutoff. After the retest date, the intermediate must be retested against its full specification. If all parameters pass, the material can continue to be used. Per WHO TRS 1010 guidance, the recommended use window after a successful retest is within one month. A full new retest period should not be assigned based on a single retest result alone.

Why do intermediates have retest dates instead of expiry dates?

ICH Q7 Section 11.61 states that “common practice is to use a retest date, not an expiration date” for APIs and intermediates. This is because intermediates are starting materials, not finished dosage forms administered to patients. If an intermediate still meets its specification after the printed date, it can still serve its function in downstream synthesis. An expiry date, by contrast, is a firm endpoint — no retesting or extension is permitted without regulatory approval.

What stability data should support a retest date on an intermediate COA?

Ideally, real-time stability data from at least 12 months of storage under ICH long-term conditions (25 °C ± 2 °C / 60% RH ± 5%). For initial assignment, accelerated stability data from 6 months at 40 °C ± 2 °C / 75% RH ± 5% may be used with extrapolation per ICH Q1E. Stress testing data characterizing the intermediate’s intrinsic degradation pathways should also be available. The stability data should cover all critical material attributes identified for that specific intermediate — purity, impurity profile, chiral purity (if applicable), residual solvents, water content, and physical form.

Is a shorter retest period a sign of lower quality?

Not necessarily. A shorter retest period often reflects a conservative assignment based on limited long-term stability data for that specific compound. A manufacturer who assigns a 12-month retest period based on 12 months of real-time data may be more scientifically rigorous than one who assigns 36 months based on extrapolation from 6 months of accelerated data alone. The key question is: what data supports the period, not how long the period is.

How does ICH Q1E extrapolation work for retest period assignment?

ICH Q1E allows extrapolation of retest periods beyond the period covered by real-time data under defined conditions. If accelerated stability data shows no significant change within 6 months, and long-term data shows little or no change with low variability, the proposed retest period may be up to twice the duration covered by long-term data — but not exceeding long-term data coverage plus 12 months. For example, 12 months of long-term data with no significant change could support a proposed retest period of up to 24 months. The extrapolated period must be verified by ongoing long-term stability data as it accumulates.

What does the 2025 ICH Q1 draft change about drug substance shelf life?

The Step 2 draft of ICH Q1 (released April 2025) expands the definition of shelf life to include drug substances, not just drug products. Previously, ICH Q1A(R2) defined shelf life only for drug products. The draft now defines shelf life as “the time period during which a drug substance or drug product is expected to remain within the approved shelf life specification.” The retest date definition remains unchanged. This change, once adopted, will formalize the concept of drug substance shelf life alongside the existing retest date concept, providing a clearer framework for stability-based time claims.

• References

  • ICH Q1A(R2) — Stability Testing of New Drug Substances and Products. International Council for Harmonisation. Available at: database.ich.org
  • ICH Q7 — Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Section 11.6: Expiry Date and Retest Date. Available at: database.ich.org
  • ICH Q1E — Evaluation of Stability Data for Establishing Retest Periods and Shelf Life. Available at: database.ich.org
  • ICH Q11 — Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities). Section 5.1.1. Available at: database.ich.org
  • ICH Q1 Step 2 Draft (April 2025) — Stability Testing of Drug Substances and Drug Products. Available at: database.ich.org
  • Charoo NA, et al. (2024). “Risk-Based Approach for Defining Retest Dates for Active Pharmaceutical Ingredients and Excipients.” Pharmaceuticals 17(7):903. Available at: mdpi.com
  • WHO Technical Report Series No. 1010 (2018). WHO Expert Committee on Specifications for Pharmaceutical Preparations — Annex 10: Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products. Available at: database.ich.org